Role of erlotinib in the management of pancreatic cancer

Therapeutics and Clinical Risk Management

Volumn 2, Issue 4, 2006, Pages 435-445

  Starling, Naureen ^a   Neoptolemos, John ^b,c   Cunningham, David ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Capecitabine; Epidermal growth factor receptor; Erlotinib; Gemcitabine; Pancreas; Pancreatic; Tarceva; Xeloda

Indexed keywords

ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIDIARRHEAL AGENT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CANERTINIB; CAPECITABINE; CETUXIMAB; CISPLATIN; CORTICOSTEROID DERIVATIVE; CYTOCHROME P450 INHIBITOR; EMOLLIENT AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ERYTHROMYCIN; FLUCONAZOLE; GEFITINIB; GEMCITABINE; GW 016; H R 3; ITRACONAZOLE; KETOCONAZOLE; LAPATINIB; MATUZUMAB; PANITUMUMAB; PELITINIB; PLACEBO; RETINOID DERIVATIVE; RIFAMPICIN;

ACNE; ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEHYDRATION; DIARRHEA; DISEASE ACTIVITY; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; FIBROSING ALVEOLITIS; FLUID THERAPY; GENETIC CODE; HUMAN; INFECTION; INTERSTITIAL PNEUMONIA; MALIGNANT TRANSFORMATION; METASTASIS POTENTIAL; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PANCREAS CANCER; PATIENT SELECTION; PHARMACOGENETICS; PNEUMONIA; PROGNOSIS; PROTEIN FUNCTION; PUSTULE; RECEPTOR BLOCKING; RECOMMENDED DRUG DOSE; REVIEW; SIGNAL TRANSDUCTION; SKIN INFECTION; SOLID TUMOR; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; VOMITING;

EID: 33845408544     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: 10.2147/tcrm.2006.2.4.435     Document Type: Review

References (69)

1. Abbas R, Fettner S, Rick M, et al. 2003. A drug-drug interaction study to evaluate the effect of rifampicin on the pharmacokinetics of the EGF receptor tyrosine kinase inhibitor, erlotinib, in healthy subjects [abstract]. Proc Am Soc Clin Oncol, 22:548.
2. Akita RW, Sliwkowski MX. 2003. Preclinical studies with erlotinib (Tarceva). Semin Oncol, 30(3 Suppl 7):15-24.
3. Albanell J, Rojo F, Averbuch S, et al. 2002. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol, 20:110-24.
4. Amador ML, Oppenheimer D, Perea S, et al. 2004. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res, 64:9139- 43.
5. Arteaga CL. 2001. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol, 19(18 Suppl):32S-40S.
6. Arteaga C. 2003. Targeting HERI/EGFR: a molecular approach to cancer therapy. Semin Oncol, 30(3 Suppl 7):3-14.
7. Baselga J. 2003. Skin as a surrogate tissue for pharmacodynamic end points: is it deep enough? Clin Cancer Res, 9:2389-90.
8. Bondar VM, Sweeney-Gotsch B, Andreeff M, et al. 2002. Inhibition of the phosphatidylinositol 3′-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther, 1:989-97.
9. Bramhall SR, Rosemurgy A, Brown PD, et al. 2001. Marimastat as first- line therapy for patients with unresectable pancreatic cancer: a randomized trial, J Clin Oncol, 19:3447-55.
10. Bramhall SR, Schulz J, Nemunaitis J, et al. 2002. A double-blind placebo- controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer, 87:161-7.
11. Bruns CJ, Harbison MT, Davis DW, et al. 2000. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res, 6:1936-48.
12. Burris HA III, Moore MJ, Andersen J, et al. 1997. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol, 15:2403-13.
13. Cheverton P, Friess H, Andras C, et al. 2004. Phase III results of exatecan (DX-8951f) versus gemcitabine in chemotherapy-naive patients with advanced pancreatic cancer [abstract]. Proc Am Soc Clin Oncol, 23:4005
14. Ciardiello F, Bianco R, Damiano V, et al. 2000. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res, 6:3739-47.
15. Ciardiello F, Caputo R, Bianco R, et al. 2000. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD- 1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res, 6:2053-63.
16. Cunningham D, Chau I, Stocken D, et al. 2005. Phase III randomised comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. Eur J Cancer, 3:12.
17. Desai B, Higgins B, Smith M. 2002. Antitumour activity of the EGFR/TK inhibitor Tarceva (erlotinib, OSI-774) tumour models [abstract]. Eur J Cancer, 38:203.
18. Dragovich T, Patnaik A, Rowinsky EK, et al. 2003. A phase I B trial of gemcitabine and erlotinib HCL in patients with advanced pancreatic adenocarcinoma and other potentially responsive malignancies [abstract]. Proc Am Soc Clin Oncol, 22:223.
19. Eberhard DA, Johnson BE, Amler LC, et al. 2005. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol, 23:5900-9.
20. Ebert MP, Fei G, Schandl L, et al. 2002. Reduced PTEN expression in the pancreas overexpressing transforming growth factor-beta 1. Br J Cancer, 86:257-62.
21. Gatzemeier U, Pluzanska A, Szczesna A, et al. 2004. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol, 22(14S)7010.
22. Guttridge DC, Albanese C, Reuther JY, et al. 1999. NF-KappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol, 19:5785-99.
23. Habib AA, Chatterjee S, Park SK, et al. 2001. The epidermal growth factor receptor engages receptor interacting protein and nuclear factor-kappa B (NF-Kappa B)-inducing kinase to activate NF-kappa B. Identification of a novel receptor-tyrosine kinase signalosome, J Biol Chem, 276:8865-74.
24. Hansen LA, Alexander N, Hogan ME, et al. 1997. Genetically null mice reveal a central role for epidermal growth factor receptor in the differentiation of the hair follicle and normal hair development. Am J Pathol, 150:1959-75.
25. Heiser PW, Hebrok M. 2004. Development and cancer: lessons learned in the pancreas. Cell Cycle, 3:270-2.
26. Herbst RS. 2003. Erlotinib (Tarceva): an update on the clinical trial program. Semin Oncol, 30(3 Suppl 7):34-46.
27. Herbst RS, Johnson DH, Mininberg E, et al. 2005. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol, 23:2544-55.
28. Herbst RS, Prager D, Hermann R, et al. 2005. TRIBUTE: a Phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol, 23:5892-9.
29. Herrmann R, Bodoky G, Ruhstaller T, et al. 2005. Gemeitabine (G) plus Capecitabine (C) versus G alone in locally advanced or metastatic pancreatic cancer. A randomized phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG) [abstract]. J Clin Oncol, 23(16S):4010.
30. Hidalgo M, Bloedow D. 2003. Pharmacokinetics and pharmacodynamics: maximizing the clinical potential of erlotinib (Tarceva). Semin Oncol, 30(3 Suppl 7):25-33.
31. Hidalgo M, Siu LL, Nemunaitis J, et al. 2001. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol, 19:3267-79.
32. Hinz M, Krappmann D, Eichten A, et al. 1999. NF-kappaB function in growth control: regulation of cyclin DI expression and G0/GI-to-S- phase transition. Mol Cell Biol, 19:2690-8.
33. Hortobagyi GN, Santer G. 2003. Challenges and opportunities for edotinib (Tarceva): what does the future hold? Semin Oncol, 30(3 Suppl 7):47- 53.
34. Jung YD, Mansfield PF, Akagi M, et al. 2002. Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. Eur J Cancer, 38:1133-40.
35. King LE Jr, Gates RE, Stoscheck CM, et al. 1990. The EGF/TGF alpha receptor in skin. J Invest Dermatol, 94(6 Suppl):164S-70S.
36. Laux I, Jain A, Singh S, et al. 2006. Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies. Br J Cancer, 94:85-92.
37. Lemoine NR, Hughes CM, Barton CM, et al. 1992. The epidermal growth factor receptor in human pancreatic cancer. J Pathol, 166:7-12.
38. LoRusso PM. 2003. Phase I Studies of ZD1839 in patients with common solid tumors. Semin Oncol, 30(1 Suppl 1):21-9.
39. Louvet C, Labianca R, Hammel P, et al. 2005. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD Phase III Trial. J Clin Oncol, 23:3509-16.
40. Lynch TJ, Bell DW, Sordella R, et al. 2004. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non- small-cell lung cancer to gefitinib. N Engl J Med, 350:2129-39.
41. Malik SN, Siu LL, Rowinsky EK, et al. 2003. Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Clin Cancer Res, 9:2478-86.
42. Marmor MD, Skaria KB, Yarden Y. 2004. Signal transduction and oncogenesis by ErbB/HER Receptors. Int J Radiat Oncol Biol Phys, 58:903-13.
43. Mendelsohn J, Baselga J. 2003. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol, 21:2787-99.
44. Mita CA, Schwartz G, Mita MM, et al. 2005. A pilot, pharmacokinetic (PK), and pharmacodynamic (PD) study to determine the feasibility of intrapatient dose escalation to tolerable rash and the activity of maximal doses of erlotinib (E) in previously treated patients with advanced non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol, 23(16S):3045
45. Miyamoto Y, Maitra A, Ghosh B, et al. 2003. Notch mediates TGF alpha- induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell, 3:565-76.
46. Moore MJ, Hamm J, Dancey J, et al. 2003. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol, 21:3296-302.
47. Moore MJ, Goldstein D, Hamm J, et al. 2005. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) [abstract]. J Clin Oncol, 23(16S):1
48. Moyer JD, Barbacci EG, Iwata KK, et al. 1997. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res, 57:4838-48.
49. Ng SS, Tsao MS, Nicklee T, et al. 2002. Effects of the epidermal growth factor receptor inhibitor OSI-774, tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. Mol Cancer Ther, 1:777-83.
50. Ogiso H, Ishitani R, Nureki O, et al. 2002. Crystal structure of the complex of human epidermal growth factor and receptor extraeellular domains. Cell, 110:775-87.
51. Overholser JP, Prewett MC, Hooper AT, et al. 2000. Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenogratt in nude mice. Cancer, 89:74-82.
52. Perez-Soler R, Saltz L. 2005. Cutaneous adverse effects With HERI/EGFR- targeted agents: is there a silver lining? J Clin Oncol, 23:5235-46.
53. Perren A, Komminoth P, Saremaslani P, et al. 2000. Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. Am J Pathol, 157:1097-103.
54. Pollack VA, Savage DM, Baker DA, et al. 1999. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther, 291:739-48.
55. Porterfield BW, Dragovich T, Patnaik A, et al. 2004. Erlotinib + gemcitabine in patients with unresectable pancreatic carcinoma: Results from a phase IB trial [abstract]. J Clin Oncol, 22(14S):4110.
56. Ratain M J, George CM, Janisch L, et al. 2002. Phase I trial of erlotinib (OSI-774) in combination with gemcitabine (G) and cisplatin (P) in patients with advanced solid tumors [abstract]. Proc Am Soc Clin Oncol, 21:2115
57. Richards DA, Kindler HL, Oettle H, et al. 2004. A randomized phase III study comparing gemcitabine plus pemetrexed versus gemcitabine in patients with locally advanced or metastatic pancreatic cancer [abstract]. Proc Am Soc Clin Oncol, 23:4007.
58. Rocha Lima CM, Green MR, Rotche R, et al. 2004. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. Clin Oncol, 22:3776-83.
59. Ruggeri BA, Huang L, Wood M, et al. 1998. Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Mol Carcinog, 21:81-6.
60. Schlieman MG, Fahy BN, Ramsamooj R, et al. 2003. Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. Br J Cancer, 89:2110-15.
61. Segaert S, Van Cutsem E. 2005. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol, 16:1425-33.
62. Shepherd FA, Pereira J, Ciuleanu TE, et al. 2004. A randomized placebo-controlled trial of erlotinib in patients with advanced non- small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) trial [abstract]. J Clin Oncol, 22(14S):7022
63. Sirotnak FM, Zakowski MF, Miller VA, et al. 2000. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD 1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res, 6:4885-92.
64. Soulieres D, Senzer NN, Vokes EE, et al. 2004. Multicenter Phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol, 22:77-85.
65. Tempero M, Plunkett W, Ruiz Van Haperen V, et al. 2003. Randomized Phase II comparison of dose-intense gemeitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol, 21:3402-8.
66. Van Cutsem E, van de Velde H, Karasek P, et al. 2004. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol, 22:1430-8.
67. Wang W, Abbruzzese JL, Evans DB, et al. 1999. The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res, 5:119-27.
68. Yamanaka Y, Friess H, Kobrin MS, 1993. Overexpression of HER2/neu oncogene in human pancreatic carcinoma. Hum Pathol, 24:1127-34.
69. Yarden Y, Sliwkowski MX. 2001. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol, 2:127-37.